{"id":17197,"date":"2013-10-24T03:30:00","date_gmt":"2013-10-24T01:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/generici-e-biosimilari-i-piu-penalizzati-dai-ritardati-pagamenti-e-dal-payback\/"},"modified":"2013-10-24T03:30:00","modified_gmt":"2013-10-24T01:30:00","slug":"generici-e-biosimilari-i-piu-penalizzati-dai-ritardati-pagamenti-e-dal-payback","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/generici-e-biosimilari-i-piu-penalizzati-dai-ritardati-pagamenti-e-dal-payback\/","title":{"rendered":"Generics and biosimilars the most penalized by late payments and payback"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"margin: 0cm 14.1pt 0pt 14.2pt\"><font size=\"3\"><font face=\"Times New Roman\"><b>Rome 02.15.2013<\/b><\/p>\n<p><\/font><\/font><\/p>\n<p class=\"MsoNormal\" align=\"right\" style=\"text-align: right; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font face=\"Times New Roman\"><b><span style=\"font-size: 14pt\">Dear you<\/span><\/b><\/p>\n<p><\/font><\/p>\n<p class=\"MsoNormal\" align=\"right\" style=\"text-align: right; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font face=\"Times New Roman\"><b><span style=\"font-size: 14pt\">&nbsp;FNOMCeO <\/span><\/b><\/p>\n<p><\/font><\/p>\n<p class=\"MsoNormal\" align=\"right\" style=\"text-align: right; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font face=\"Times New Roman\"><b><span style=\"font-size: 14pt\">OO.SS. Doctors<\/span><\/b><\/p>\n<p><\/font><\/p>\n<p class=\"MsoNormal\" style=\"margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font size=\"3\"><font face=\"Times New Roman\"><b>&nbsp;<\/b><\/p>\n<p><\/font><\/font><\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><b><font size=\"3\"><font face=\"Times New Roman\">SUBJECT: Renewal of the Chemical\/Pharmaceutical CCNL - New duties for Pharmaceutical Representatives - Serious critical elements in relations with the Medical Class.<\/p>\n<p><\/font><\/font><\/b><\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\">\n<p><font size=\"3\" face=\"Times New Roman\">&nbsp;<\/font><\/p>\n<\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font size=\"3\"><font face=\"Times New Roman\">The recent renewal of the National Collective Labor Agreement for the chemical-pharmaceutical sector radically changes the duties of Pharmaceutical Representatives employed by Pharmaceutical Companies.<\/p>\n<p><\/font><\/font><\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font size=\"3\"><font face=\"Times New Roman\">A process of modification of the role of the ISFs has already been underway for several years with the aim of assigning them commercial tasks contrary to what is explicitly provided for by current regulations (Legislative Decree 219\/06 and various regional regulations) as well as the common sense deriving from the need to contain pharmaceutical expenditure and trivial criteria of professional ethics.<\/p>\n<p><\/font><\/font><\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font size=\"3\"><font face=\"Times New Roman\">With the ongoing contract renewal, we go much further by explicitly asking the ISFs to <i>\u201ccollect and bring back\u201d<\/i> the <i>&quot;therapeutic choices&quot;<\/i> of the doctor visited under the pretext that this would be done <i>&quot;with a view to assigning the patient to the best access to care&quot;<\/i>.<\/p>\n<p><\/font><\/font><\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify; margin: 0cm 14.1pt 0pt 14.2pt; mso-margin-top-alt: auto; mso-margin-bottom-alt: auto\"><font size=\"3\"><font face=\"Times New Roman\">After many ISF assemblies, in various company realities, reaffirming the validity of the regulations in force on the subject, have expressed their opposition to this topic, an inter-company and inter-union coordination of the elected ISFs was set up, as RSU, on behalf of all trade unions, in many pharmaceutical companies.<\/p>\n<p><\/font><\/font><\/p>\n<p","protected":false},"excerpt":{"rendered":"<p>Roma 15.02.2013 Spett.li &nbsp;FNOMCeO OO.SS. Medici &nbsp; OGGETTO: Rinnovo CCNL Cimico\/Farmaceutico &ndash; Nuove mansioni per gli Informatori Scientifici del Farmaco &#8211; Gravi elementi di criticit&agrave; nei rapporti con la Classe Medica. &nbsp; Il recente rinnovo del CCNL del comparto chimico-farmaceutico, vede radicalmente modificate le mansioni degli Informatori Scientifici del Farmaco dipendenti delle Aziende Farmaceutiche. Gi&agrave; &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17197"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17197\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}